Mangrove Partners Bellus Health Inc. Call Options Transaction History
Mangrove Partners
- $890 Million
- Q2 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding BLU
# of Institutions
1Shares Held
128KCall Options Held
0Put Options Held
0About BELLUS Health Inc.
- Ticker BLU
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 125,793,000
- Description
- BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...